(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/160881 A9

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61P 31/10* (2006.01)
A61P 31/04 (2006.01) *A61P 31/12* (2006.01)

(21) International Application Number:
PCT/EP2021/053633

(22) International Filing Date:
15 February 2021 (15.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20157300.3 14 February 2020 (14.02.2020) EP

(71) Applicant: **ETHERNA IMMUNOTHERAPIES NV** [BE/BE]; Galileilaan 19, 2845 Niel (BE).

(72) Inventors: **TIEST, Wim**; Galileilaan 19, 2845 Niel (BE).
VAN HOORICK, Diane; Galileilaan 19, 2845 Niel (BE).

(74) Agent: **ARNOLD & SIEDSMA BV**; Bezuidenhoutseweg 57, 2594 AC The Hague (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
10 November 2022 (10.11.2022)

(15) Information about Correction:
see Notice of 10 November 2022 (10.11.2022)

WO 2021/160881 A9

(54) Title: INTRANASAL MRNA VACCINES

(57) Abstract: The present invention in general to intranasal mRNA vaccines, more in particular comprising one or more immunostimulatory molecules, one or more pathogenic antigens and a specifically designed delivery system. Specifically said immunostimulatory molecules and pathogenic antigens are provided for in the form of mRNA molecules encoding such molecules and antigen; more in particular mRNA molecules encoding for CD40L, caTLR4 and/or CD70 in combination with one or more mRNA molecules encoding a bacterial, viral or fungal antigen. Specifically said, the delivery is a mixture of chemical compounds that allow protection and deposition of the vaccine and targeting to the antigen presenting cells in the nose. In particular, present invention is well suited for development of a rapid response vaccine in an outbreak setting.